TL;DR
Get oils, diffusers and self-care delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA classified a recall of Vitruvias Therapeutics’ thyroid tablets as Class I, its most serious category. A study found nearly 17% of adolescents on GLP-1 drugs developed a nutritional deficiency within a year, and the ADA and EASD issued updated type 1 diabetes guidelines for adults.
The FDA has designated Vitruvias Therapeutics’ recall of a lot of 30-mg levothyroxine-liothyronine tablets as Class I, its most serious classification, according to a roundup of endocrinology news published by MedPage Today on September 29, 2026 citing USA Today. The designation means exposure to the product carries a reasonable probability of serious adverse health consequences or death.
The recalled product is a lot of combination thyroid tablets containing both levothyroxine and liothyronine, used for thyroid hormone replacement. The FDA’s Class I designation is reserved for the most dangerous recalls. Details on how many patients or pharmacies are affected were not included in the roundup.
In obesity medicine research, a study published in Childhood Obesity found that nearly 17% of adolescents taking a GLP-1 drug were diagnosed with at least one nutritional deficiency — most frequently vitamin D deficiency — within the first year of starting the medication. Separately, a preprint posted at Preprints.org suggested that a patient’s weight trajectory before starting a GLP-1 drug may help predict whether they become a “super responder.”
The American Diabetes Association and the European Association for the Study of Diabetes (EASD) issued updated joint consensus guidelines for managing type 1 diabetes in adults, published in Diabetes Care. The roundup did not detail the specific changes from prior guidance.
Why Patients on Thyroid Drugs Should Check Now
Thyroid tablets are taken daily by patients who depend on consistent hormone dosing; a Class I recall signals the FDA believes the product could cause serious harm. Patients filling combination levothyroxine-liothyronine prescriptions may need to verify their lot numbers with pharmacies.
The adolescent nutrition findings add to growing scrutiny of GLP-1 drugs in younger populations, where rapid weight loss can affect nutrient intake. The new T1D guidelines are the reference standard many clinicians use for adult type 1 diabetes care, so practice changes may follow.
A Heavy Week in Obesity Drug Competition
The roundup came amid intense competition between Eli Lilly and Novo Nordisk. At the EASD annual meeting, Lilly reported that tirzepatide (Zepbound) yielded greater weight loss than semaglutide (Wegovy HD) in an indirect comparison of trials — a method that compares results across separate studies rather than head-to-head. Lilly also said its oral GLP-1 drug orforglipron (Foundayo) showed greater weight loss and HbA1c reduction versus oral semaglutide (Rybelsus) in an indirect comparison of type 2 diabetes trials.
Novo Nordisk countered that adults with type 2 diabetes on semaglutide (Ozempic) who doubled their dose had a lower risk of major adverse cardiovascular events compared with those switching to tirzepatide (Mounjaro). Viking Therapeutics said phase II trial participants on its investigational dual-acting obesity drug maintained virtually all weight loss after switching from weekly injections to less frequent dosing, while Roche halted development of emugrobart, a muscle-building drug intended to pair with GLP-1/GIP agonists, after a disappointing interim phase II analysis.
“The FDA designated Vitruvias Therapeutics’ recall of a lot of 30-mg levothyroxine-liothyronine tablets as Class I, its most serious classification.”
— MedPage Today roundup (citing USA Today)
What the Studies Do Not Yet Show
The reason for the thyroid tablet recall — such as potency deviation, contamination, or mislabeling — was not stated in the roundup, nor were injury reports or distribution details. The GLP-1 “super responder” findings come from a preprint that has not undergone peer review.
The Lilly and Novo Nordisk comparisons are indirect comparisons across separate trials, which are weaker evidence than head-to-head randomized studies. The Viking Therapeutics and Roche results are from phase II trials, which typically do not confirm efficacy at scale.
What’s Next
The recall will proceed through FDA enforcement and pharmacy-level notification; patients can expect updated lot and distribution information from the agency or Vitruvias. The peer-reviewed status of the weight-trajectory preprint and full publication of the adolescent nutrition study may clarify GLP-1 monitoring recommendations.
Clinicians will begin implementing the updated ADA/EASD adult T1D guidelines, and Lilly, Novo Nordisk, and Viking are expected to continue late-stage trials that could support head-to-head or label-change filings.
Key Questions
What does an FDA Class I recall mean?
Class I is the FDA’s most serious recall category, indicating a reasonable probability that using the product could cause serious adverse health consequences or death.
Which thyroid medication was recalled?
A lot of Vitruvias Therapeutics’ 30-mg levothyroxine-liothyronine tablets (Thyroid Tablets). Patients should check with their pharmacy to see whether their prescription is affected.
Do GLP-1 drugs cause vitamin deficiencies in teens?
A study in Childhood Obesity found nearly 17% of adolescents on GLP-1 drugs were diagnosed with at least one nutritional deficiency within a year — most often vitamin D. The study shows an association; patients on these drugs should discuss monitoring with their clinician.
Are the new type 1 diabetes guidelines for children or adults?
The updated ADA and EASD joint consensus guidelines address management of type 1 diabetes specifically in adults, published in Diabetes Care.
Is tirzepatide proven better than semaglutide for weight loss?
Not directly. Eli Lilly reported greater weight loss for tirzepatide versus semaglutide in an indirect comparison of separate trials presented at EASD, which is weaker evidence than a head-to-head trial.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
